RE: If holding is stressful, imagine not holding and trying to time the RNS!18 May 2020 09:24
The is not just about Covid
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces the first data results from in vivo testing of its CDX bi-specific antibody (“CDX antibody”) product candidate for the treatment of Acute Myeloid Leukemia (“AML”), a form of blood cancer. This follows the successful in vitro testing of the CDX antibody for the treatment of Acute Lymphoblastic Leukemia (“ALL”) announced on 30 May 2019.
The first data results demonstrate that the CDX antibody is capable of eliminating a subset of AML cells in vivo. The CDX antibody was shown to target AML cells that overexpress the protein FLT3. The CDX antibody binds to the FLT3 protein that is located on the surface of unwanted (target) cells, binds to the CD3 protein on the surface of T-cells, and ultimately redirects T-cells to kill the target cells. The Company has verified the efficacy of CDX against AML in vivo, using its proprietary advanced hematopoietic chimeric (“AHC”) mice (humanized mice).
Background on Acute Myeloid Leukemia
AML affected about one million people globally in 2015 and resulted in 147,000 deaths. AML accounts for roughly 1.8% of cancer deaths in the United States with more than 20,000 new cases diagnosed in the US and 18,000 cases in Europe every year.
Despite numerous advances in understanding the biology and pathogenesis of AML, treatment remains unsatisfactory. Relapsed or refractory (R/R) AML is nearly universally fatal. The only curative treatment is allogeneic hematopoietic stem cell transplantation (HSCT) with success rates less than 30% in the patients with chemo-sensitive disease. Unfortunately, most patients lack sensitivity to currently available therapies and therefore do not consider transplant or have extremely poor outcomes following allogeneic HSCT. The Directors believe that the Company’s CDX antibody could replace traditional methods of treatment of relapsed/refractory AML.
It is estimated that the value of the global therapeutic market for AML was about $700M in 2018 and expected to grow to more than $1.5B by 2024.
Vladislav Sandler, Chief Executive Officer, commented, “We are encouraged by this new data which demonstrates our continuing progress in the development and potential uses of our CDX antibody. We previously demonstrated that the CDX antibody may be effective in treating AML in vitro. Our new data demonstrates CDX antibody efficacy when tested in vivo in our own proprietary AHC model. This antibody should, if successful, provide a new and potentially effective treatment for a form of blood cancer for which survival rates are currently poor.”
RE: hmms, see alot of nervous ones here...the ones18 May 2020 06:39
The firm runs a state of the art research facility in what is now coronavirus central: New York City, and has not stopped work throughout the outbreak of the pandemic. Even without its COVID 19-related work, Hemogenyx Pharmaceuticals interests us because of its expertise in stem cell-related solutions for severe blood diseases and its focus on pre-clinical stage medicines and treatments for autoimmune diseases.
Autoimmune conditions such as lupus, type 1 diabetes and multiple sclerosis are unfortunately on the rise. There is no good explanation as to why, but this type of disease is about three times more common now than only a few decades ago, and yet is fairly costly to treat because it requires life-long medication.
Hemogenyx Pharmaceuticals already has good links with the rest of the biotech industry and is collaborating with partners like Johnson and Johnson, the University of Oxford and LakeParma on various projects. This will position it as an interesting investment not only in the short term but also once the corona dust has settled.